Status:

COMPLETED

Hilotherapy-study on Prevention of Oxaliplatin-induced Peripheral Neuropathy

Lead Sponsor:

Universitaire Ziekenhuizen KU Leuven

Conditions:

Quality of Life

Chemotherapy-induced Peripheral Neuropathy

Eligibility:

All Genders

18+ years

Phase:

NA

Brief Summary

Effectiveness of hilotherapy for the prevention of oxaliplatin-induced peripheral neuropathy and pain in the treatment of gastrointestinal tumors: A randomized controlled trial.

Detailed Description

This study investigates whether constant cooling of the hands and feet using Hilotherm ChemoCare devices reduces the incidence of (severe) oxaliplatin-induced peripheral neuropathy and pain compared t...

Eligibility Criteria

Inclusion

  • Most important Eligibility Criteria:
  • 18 years or older
  • Gastro-intestinal tumor, treated in UZ Leuven (University Hospitals of Leuven)
  • Starting oxaliplatin-based treatment

Exclusion

  • Already grade 2 or higher peripheral neuropathy
  • For a more detailed list, see protocol.

Key Trial Info

Start Date :

May 17 2021

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

October 25 2022

Estimated Enrollment :

66 Patients enrolled

Trial Details

Trial ID

NCT04913376

Start Date

May 17 2021

End Date

October 25 2022

Last Update

July 3 2024

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

UZ Leuven

Leuven, Flemish-Brabant, Belgium, 3000

Hilotherapy-study on Prevention of Oxaliplatin-induced Peripheral Neuropathy | DecenTrialz